- Home
- DNTH vs FLR Comparison
DNTH vs FLR Comparison
Compare DNTH & FLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | FLR |
|---|---|---|
| Founded | 2015 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 7.0B |
| IPO Year | 2018 | 2006 |
Fundamental Metrics
Financial Performance| Metric | DNTH | FLR |
|---|---|---|
| Price | $77.07 | $44.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $140.80 | $61.56 |
| AVG Volume (30 Days) | 865.0K | ★ 2.2M |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.89 |
| Revenue | $2,036,000.00 | ★ $15,503,000,000.00 |
| Revenue This Year | N/A | $7.68 |
| Revenue Next Year | N/A | $9.93 |
| P/E Ratio | ★ N/A | $22.96 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.28 | $39.33 |
| 52 Week High | $117.88 | $58.35 |
Technical Indicators
Market Signals| Indicator | DNTH | FLR |
|---|---|---|
| Relative Strength Index (RSI) | 33.18 | 33.06 |
| Support Level | $75.50 | $43.13 |
| Resistance Level | $91.36 | $53.95 |
| Average True Range (ATR) | 4.05 | 1.82 |
| MACD | 0.51 | -0.48 |
| Stochastic Oscillator | 40.47 | 16.73 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
About FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.